HK1171185A1 - 抗腫瘤效果增强劑 - Google Patents

抗腫瘤效果增强劑

Info

Publication number
HK1171185A1
HK1171185A1 HK12111795.0A HK12111795A HK1171185A1 HK 1171185 A1 HK1171185 A1 HK 1171185A1 HK 12111795 A HK12111795 A HK 12111795A HK 1171185 A1 HK1171185 A1 HK 1171185A1
Authority
HK
Hong Kong
Prior art keywords
tumor effect
effect potentiator
potentiator
tumor
effect
Prior art date
Application number
HK12111795.0A
Other languages
English (en)
Inventor
福岡正哲
橫川達史
宫原成司
宫腰均
矢野稚子
田口淳子
高尾彌生
Original Assignee
大鵬藥品工業株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大鵬藥品工業株式會社 filed Critical 大鵬藥品工業株式會社
Publication of HK1171185A1 publication Critical patent/HK1171185A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12111795.0A 2009-11-30 2012-11-20 抗腫瘤效果增强劑 HK1171185A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009272738 2009-11-30
PCT/JP2010/071280 WO2011065541A1 (ja) 2009-11-30 2010-11-29 抗腫瘍効果増強剤

Publications (1)

Publication Number Publication Date
HK1171185A1 true HK1171185A1 (zh) 2013-03-22

Family

ID=44066645

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12111795.0A HK1171185A1 (zh) 2009-11-30 2012-11-20 抗腫瘤效果增强劑
HK14109161.8A HK1195733A1 (zh) 2009-11-30 2014-09-11 抗腫瘤效果增强劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK14109161.8A HK1195733A1 (zh) 2009-11-30 2014-09-11 抗腫瘤效果增强劑

Country Status (15)

Country Link
US (1) US8883759B2 (zh)
EP (2) EP3673908B1 (zh)
JP (1) JP5336606B2 (zh)
KR (1) KR101701549B1 (zh)
CN (2) CN103948599B (zh)
AU (1) AU2010323454B2 (zh)
BR (1) BR112012013049A2 (zh)
CA (1) CA2782280C (zh)
ES (2) ES2788549T3 (zh)
HK (2) HK1171185A1 (zh)
MX (1) MX2012006183A (zh)
MY (1) MY161094A (zh)
RU (1) RU2548913C2 (zh)
TW (1) TWI466870B (zh)
WO (1) WO2011065541A1 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101384940B1 (ko) * 2008-06-03 2014-04-11 다이호야쿠힌고교 가부시키가이샤 인간 데옥시우리딘 트리포스파타아제 저해 활성을 갖는 신규 우라실 화합물 또는 그 염
MX2012006183A (es) 2009-11-30 2012-06-19 Taiho Pharmaceutical Co Ltd Potenciador del efecto antitumoral.
WO2014107622A1 (en) * 2013-01-07 2014-07-10 University Of Southern California Deoxyuridine triphosphatase inhibitors
CN106061952B (zh) 2014-01-03 2022-01-28 南加州大学 含有杂原子的脱氧尿苷三磷酸酶抑制剂
US20180110780A1 (en) * 2015-04-30 2018-04-26 Taiho Pharmaceutical Co., Ltd. Agent for alleviating side effect of antitumor drug
US10259792B2 (en) 2015-05-01 2019-04-16 Taiho Pharmaceutical Co., Ltd. Crystal of uracil compound
WO2017006283A1 (en) 2015-07-08 2017-01-12 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
CN107922330A (zh) 2015-07-08 2018-04-17 Cv6治疗(Ni)有限公司 含乙内酰脲的脱氧尿苷三磷酸酶抑制剂
US10577321B2 (en) 2015-07-08 2020-03-03 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2017006271A1 (en) * 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用
WO2017119484A1 (ja) 2016-01-08 2017-07-13 大鵬薬品工業株式会社 免疫調節剤を含有する抗腫瘍剤及び抗腫瘍効果増強剤
WO2018098208A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
US11168059B2 (en) 2016-11-23 2021-11-09 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
US11174271B2 (en) 2016-11-23 2021-11-16 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
WO2018098207A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098206A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018128720A1 (en) 2017-01-05 2018-07-12 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
JP2019206516A (ja) 2018-05-23 2019-12-05 国立大学法人高知大学 膵癌細胞の浸潤転移抑制剤
RU2706339C1 (ru) * 2019-07-24 2019-11-18 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ ИМЕНИ АКАДЕМИКА А.М. ГРАНОВА" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ им. ак. А.М. Гранова" Минздрава России Способ лечения операбельной аденокарциномы головки поджелудочной железы
JP2023040314A (ja) * 2020-02-18 2023-03-23 大鵬薬品工業株式会社 ウラシル誘導体化合物を含有する抗腫瘍効果増強剤
JP2023531522A (ja) 2020-06-26 2023-07-24 シーブイ6 セラピューティクス (エヌアイ) リミテッド デオキシウリジントリホスファターゼ阻害剤との併用療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5839672A (ja) * 1981-09-03 1983-03-08 Chugai Pharmaceut Co Ltd ウラシル誘導体
JPH09286786A (ja) * 1996-04-18 1997-11-04 Nippon Paper Ind Co Ltd ピリミジン誘導体及びその抗腫瘍剤としての用途
RU2102390C1 (ru) * 1996-06-06 1998-01-20 Научно-исследовательская лаборатория иммунохимиотерапии лепры и иммунотропных средств с клиникой и опытно-экспериментальным производством МЗМП России N-(6-метил-2,4-диоксо-1,2,3,4-тетрагидропиримидинил-5-сульфонил) пиразин-2-карбоксамид, обладающий противолепрозной, противотуберкулезной и иммунотропной активностью, способ его получения
GB0400290D0 (en) 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
EP1939186A1 (en) * 2006-12-22 2008-07-02 Sulfidris S.r.l. 5-Fluorouracil derivatives and their use for the treatment of cancer
KR101384940B1 (ko) * 2008-06-03 2014-04-11 다이호야쿠힌고교 가부시키가이샤 인간 데옥시우리딘 트리포스파타아제 저해 활성을 갖는 신규 우라실 화합물 또는 그 염
JP2013032293A (ja) * 2009-11-30 2013-02-14 Taiho Yakuhin Kogyo Kk ヒトdUTPase阻害活性を有する5−フルオロウラシル化合物又はその塩
MX2012006183A (es) 2009-11-30 2012-06-19 Taiho Pharmaceutical Co Ltd Potenciador del efecto antitumoral.
JP5839672B2 (ja) * 2011-09-28 2016-01-06 株式会社日立製作所 低真空軟x線実験装置

Also Published As

Publication number Publication date
TW201124387A (en) 2011-07-16
CN102612369A (zh) 2012-07-25
TWI466870B (zh) 2015-01-01
BR112012013049A2 (pt) 2016-11-22
EP3673908B1 (en) 2022-01-12
CN103948599B (zh) 2016-03-09
RU2012127309A (ru) 2014-01-10
EP2508185A1 (en) 2012-10-10
KR101701549B1 (ko) 2017-02-01
CN103948599A (zh) 2014-07-30
CA2782280A1 (en) 2011-06-03
JPWO2011065541A1 (ja) 2013-04-18
WO2011065541A1 (ja) 2011-06-03
AU2010323454A2 (en) 2012-06-14
AU2010323454B2 (en) 2014-05-08
EP2508185A4 (en) 2016-05-25
US20120225838A1 (en) 2012-09-06
EP2508185B1 (en) 2020-03-04
EP3673908A1 (en) 2020-07-01
ES2788549T3 (es) 2020-10-21
US8883759B2 (en) 2014-11-11
CA2782280C (en) 2019-02-26
HK1195733A1 (zh) 2014-11-21
JP5336606B2 (ja) 2013-11-06
RU2548913C2 (ru) 2015-04-20
CN102612369B (zh) 2014-06-18
ES2906227T3 (es) 2022-04-13
MY161094A (en) 2017-04-14
KR20120116925A (ko) 2012-10-23
MX2012006183A (es) 2012-06-19
AU2010323454A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
HK1195733A1 (zh) 抗腫瘤效果增强劑
DK3023438T3 (en) Anti-gitr-antistoffer
DK2457337T3 (en) Specialtilpasset impuls-burst
EP2462514A4 (en) GREEN BOOKS
EP2443235A4 (en) ß-glucosidase VARIANTS
EP2515891A4 (en) 3-keto-N-propargyl-1-aminoindan
EP2508411A4 (en) STRUCTURE
EP2519921A4 (en) CALL TRACING
DK2464943T3 (en) Systemintegration
GB201011356D0 (en) Ventalation arrangements
GB0900568D0 (en) Poymerisation
GB0900319D0 (en) Hydrocharger
EP2510125A4 (en) HYPER PRIMER
AU4240P (en) Tuckerbox xTriticosecale
AU4925P (en) Bonscawi Scaevola aemula
AU4926P (en) Bonscalib Scaevola aemula
AU4924P (en) Bonscablue Scaevola aemula
TWM372073U (en) Covering structure
GB0900167D0 (en) B b
PL387107A1 (pl) Profil
GB0921748D0 (en) Switch-actuated arrangements
ZA201008616B (en) Structure
TWM373647U (en) Insect-trapping structure
GB0920959D0 (en) ERoof structure
TWM371434U (en) Sun-hat structure